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Osteopontin is a proinflammatory cytokine and plays a pathogenetic role in multiple sclerosis and its animal model, experimental
autoimmune encephalomyelitis (EAE), by recruiting autoreactive T cells into the central nervous system.Osteopontin functions are
modulated by thrombin cleavage generating N- and C-terminal fragment, whose individual roles are only partly known. Published
data are difficult to compare since they have been obtained with heterogeneous approaches. Interestingly, thrombin cleavage of
osteopontin unmasks a cryptic domain of interaction with 𝛼
4
𝛽
1
integrin that is themain adhesionmolecule involved in lymphocyte
transmigration to the brain and is the target for natalizumab, the most potent drug preventing relapses. We produced recombinant
osteopontin and its N- and C-terminal fragments in an eukaryotic system in order to allow their posttranslational modifications.
We investigated, in vitro, their effect on human cells and in vivo in EAE. We found that the osteopontin cleavage plays a key role in
the function of this cytokine and that the two fragments exert distinct effects both in vitro and in vivo. These findings suggest that
drugs targeting each fragment may be used to fine-tune the pathological effects of osteopontin in several diseases.
1. Introduction
Osteopontin (OPN) is a matricellular protein originally iso-
lated from the bone, expressed by various cell types including
macrophages, dendritic cells, and activated T cells. OPN
mediates several biological functions such as bone remodel-
ing, macrophage response, cell migration, and adhesion, and
it is involved in the pathogenesis of several diseases including
atherosclerosis, cancer, chronic inflammatory diseases, and
several autoimmune diseases [1–3]. OPN costimulates T cell
activation and supports differentiation of proinflammatory T
helper 1 (Th1) andTh17 cells [4, 5].
OPN is a member of the SIBLING (Small Integrin Bind-
ing Ligand N-linked Glycoprotein) protein family. It has two
calcium binding sites, two putative heparin binding domains,
and multiple adhesion motifs which allow interaction with
several receptors and cell types [6]. OPN biological functions
are influenced by posttranslational modifications, such as
phosphorylation, glycosylation, and protein cleavage medi-
ated by thrombin and metalloproteinases [7–9]. OPN has
RGD (arginine-glycine-aspartate) integrin binding domain,
through which it mediates interactions with 𝛼v𝛽1, 𝛼v𝛽3,
𝛼v𝛽5, 𝛼v𝛽6, 𝛼8𝛽1, and 𝛼5𝛽1 integrins [10–13]. Moreover,
𝛼9𝛽1, 𝛼4𝛽1, and 𝛼4𝛽7 integrins bind to a cryptic SVVYGLR
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(SLAYGLR in mice) sequence which is exposed upon throm-
bin cleavage occurring at the Arg168-Ser169 site near to the
RGD motif [14–16]. This cleavage generates two fragments,
the N- and C-terminal, displaying functional differences
from the full length protein [17]. The N-terminal fragment
(OPN-N, approx. 35 kDa) binds to integrins through the
RGD or the cryptic binding site, promotes IFN-𝛾 secretion
in T cells, and stimulates cell migration by binding to
𝛼9𝛽1 and 𝛼4𝛽1 [18, 19]. The C-terminal fragment (OPN-C,
approx. 25 kDa) inhibits IL-10 secretion and stimulates cell-
cell adhesion by interacting with CD44 isoforms containing
the v6 and v7 domains [20, 21].
OPN is highly expressed in several tumors, where it can be
cleaved by thrombin and acts as a proangiogenic factor [22–
25]. Moreover, the OPN:CD44 interaction promotes metas-
tasis dissemination in a variety of malignancies [26]. The
individual role of OPN-N and OPN-C has been investigated
mainly in cancer cells because of the expression of both OPN
and activated thrombin in the microenvironment of several
tumors [22, 27, 28]. On the contrary, little information is
available on their role in autoimmune diseases. Full length
OPN (OPN-FL) is expressed at similar levels in the synovial
fluid of patients with rheumatoid arthritis (RA) and in
those with osteoarthritis, but OPN-N levels in RA synovial
fluid samples are around 30-fold higher than in those from
osteoarthritis and correlate with the disease status [29].
A considerable body of evidence suggests that OPN plays
a detrimental role in multiple sclerosis (MS) and its animal
model, experimental autoimmune encephalomyelitis (EAE)
[30–32]. In MS lesions, high OPN levels are present in
the perivascular cuff that surrounds inflamed blood vessels,
contains inflammatory lymphocytes, and is delimited by
the endothelium and the basement membrane. At this site,
OPN plays a role in lymphocyte recruitment into the MS
lesion, which involves 𝛼4𝛽1 integrin that is the target of
the anti-MS drug natalizumab, a humanized monoclonal
antibody that has had benefic effects for relapses prevention
in RR-MS [33]. OPN binds to 𝛼4𝛽1 integrin only upon
cleavage by thrombin which unmasks two 𝛼4𝛽1 integrin
binding sites located into the N-terminal fragment. Hur et
al. showed that the administration of recombinant OPN-FL
exacerbates EAE, but the relative role of OPN-N and OPN-
C is not known [34]. However, thrombin-mediated cleavage
may play a role, since thrombin activity increases with the
progression of neuroinflammation, and it is detectable in
the demyelinating lesions where also OPN is present at
high levels [35, 36]. Moreover, in vivo administration of
hirudin, a thrombin inhibitor, decreases clinical severity,
demyelination, and secretion ofTh1- andTh17-type cytokines
in EAE [37, 38].
OPN modulates several cell activities in vitro, but the
role of OPN cleavage and the relative role of OPN-C and
OPN-N are only partly known. Moreover, several available
data are difficult to compare because they have been obtained
with heterogeneous approaches, such as antibody-mediated
blockage of the OPN receptors, use of OPNs produced in
bacteria and eukaryotic cells, which influence the posttrans-
lational modifications involved in OPN function, or use of
a mixture of OPN fragments obtained by in vitro treatment
with thrombin.
The aim of our research was to recapitulate, in vitro,
the OPN effects on human cells with a particular focus on
processes involved inMS relapse, that is, T cell andmonocyte
activation, T cell apoptosis, lymphocytes, and endothelial
cell migration and adhesion, by using recombinant forms of
OPN-FL, OPN-N, and OPN-C produced in an eukaryotic
system in order to ensure their posttranslationmodifications.
Moreover, we investigated the activity of these OPNs
and a point-mutated form of OPN resistant to thrombin
cleavage (OPN-FLmut) on the EAE course in vivo in mice,
since the functional in vivo role of theOPNcleavage andOPN
fragments is far from being elucidated.
2. Materials and Methods
2.1. Production of Human and Murine Recombinant Proteins.
Both human and mouse OPN cDNAs were purchased from
imaGenes GmBH, Germany. The coding sequences lacking
the signal sequence, of the OPN full length (OPN-FL) and
the two thrombin-cleaved fragments (OPN-N and OPN-
C), were amplified by PCR with specific oligonucleotides
and cloned into pMB-SV5 vector [39] downstream from the
immunoglobulin leader sequence.The thrombin-uncleavable
OPN constructs (OPN-FLmut) was generated by mutating
the mouse OPN sequence from AGGTCA coding for amino
acids R
153
and S
154
to the AGCTTT coding for S
153
and
F
154
. This substitution has been described as yielding a
thrombin cleavage resistant OPN [23]. In order to introduce
the mutation, we performed site-directed mutagenesis using
a mutagenic oligonucleotide specific for each sequence in
combination with the reverse oligonucleotide mapping on
the C-terminal end of the molecule. After amplification and
restriction digestion, eachmutated fragment was ligated with
the wild-type upstream fragment obtained by restriction
digestion to reconstitute the full length sequence. All these
OPN constructs were subsequently amplified with specific
oligonucleotides and cloned as six histidine- (6xHis-) tagged
molecules into pUCOE vector [40]. For this cloning, we
used a common forward oligonucleotide annealing on the
Kozak sequence of the pMB-SV5 vector and a specific reverse
oligonucleotide carrying 6xHis sequence. Recombinant OPN
molecules were produced in Chinese Hamster Ovary Sus-
pension Cells (CHOs; Invitrogen, Burlington, ON, Canada,
USA). Cells were cultured in CHOS-SFMII medium (Invit-
rogen) and transfectedwith the pUCOE-OPN6xHis plasmids
using FreeStyle MAX Reagent (Invitrogen) according to the
manufacturer’s instructions. To maintain stable transgene
expression, transfected cells were cultured under selective
pressure using 200𝜇g/mL of hygromycin B (Invitrogen). The
presence of each recombinant OPN construct in the cell
supernatant was verified by western blotting using either
an antibody directed against the His tag (Tetra-His Anti-
body, Qiagen, Valencia, CA, USA) or an anti-OPN antibody
directed against an epitope located in the N- or C-terminal
half of the molecule: SPP1 Polyclonal Antibody (Invit-
rogen) and Polyclonal Anti-Osteopontin Antibody (Milli-
pore, Billerica, MA, USA), respectively. These antibodies
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were detected using the appropriate horseradish peroxidase-
conjugated secondary antibody (Sigma-Aldrich, St. Louis,
MO, USA). The reactive proteins were visualized by the
ECL (Perkin Elmer, Waltham, MA, USA). All recombinant
proteins were correctly recognized, and they displayed the
expected size (i.e., 60 kDa for OPN-FL and OPN-FLmut,
35 kDa forOPN-N, and 25 kDa forOPN-C).Cellswere grown
at high density using CELLine devices (BD Biosciences,
San Diego, CA, USA) and collected twice a week. After
centrifugation at 400×g for 10 minutes, cell supernatants
were collected and each recombinant protein was purified
on HIS Trap Excel Ni-Sepharose resin (GE Healthcare,
Uppsala, Sweden), dialyzed overnight against PBS, and
analyzed by western blotting and coomassie gel staining
(Sigma-Aldrich).
2.2. Cells. Peripheral blood mononuclear cells (PBMCs)
were separated from human blood samples obtained from
healthy donors, who signed their written informed consent,
by density gradient centrifugation using the Ficoll-Hypaque
reagent (Lympholyte-H, Cedarlane Laboratories, Burlington,
ON, Canada). The use of PBMCs was approved by the
ethics committee of the “Azienda Ospedaliera Universitaria
Maggiore della Carita`” of Novara (Prot. 962/CE). CD4+ T
cells and monocytes were negatively purified from PBMCs
using the EasySepHuman CD4 Negative Selection Kit and
EasySep Human CD14 Negative Selection Kit, respectively
(Stem Cells Technologies, Vancouver, BC, USA). Cell purity
was checked by immunophenotypic analyses and was higher
than 95%. Peripheral blood lymphocytes (PBL)were obtained
from PBMC after 2 h adhesion to remove monocytes. Cul-
tures were performed in RPMI 1640 supplemented with
10% fetal bovine serum (FBS), and 100U/mL penicillin,
100 𝜇g/mL streptomycin (Invitrogen). For interferon- (IFN-)
𝛾, interleukin- (IL-) 17A, and IL-10 secretion and intracellular
staining, 0.1×106 CD4+ T cells were activated with anti-CD3
(1 𝜇g/mL, clone: OKT3) and anti-CD28 (2 𝜇g/mL, Ancell,
Bayport, MN, USA) in the presence or absence of OPN-FL
1 𝜇g/mL, OPN-N, or OPN-C 0.5 𝜇g/mL for 5 days. For Tissue
Inhibitor Metalloproteinase-1 (TIMP-1) and IL-6 secretion,
0.1×10
6monocytes were cultured in the presence or absence
ofOPN-FL 1𝜇g/mL,OPN-N, orOPN-C0.5 𝜇g/mL for 2 days.
The effects ofOPN-FLwere compared to that of a commercial
OPN-FL purchased from R&D System, and we obtained the
same results.
Human umbilical vein endothelial cells (HUVECs) were
isolated from human umbilical veins via trypsin treatment
(1%) and cultured inM199medium (Sigma-Aldrich) with the
addition of 20% FCS (Invitrogen) and 100U/mL penicillin,
100 𝜇g/mL streptomycin, 5UI/mL heparin, 12 𝜇g/mL bovine
brain extract, and 200mMglutamine (HyClone Laboratories,
South Logan, USA). Cells were grown to confluence in flasks
and used at the 2nd–5th passage. The purity of the EC prepa-
ration was evaluated using morphologic criteria and positive
immunofluorescence for factor VIII. Contamination with
blood leukocytes was assessed via immunofluorescence with
an anti-CD45 antibody. The use of HUVECs was approved
by the institutional review board of the “Presidio Ospedaliero
Martini” of Turin (Prot. 263-07/NF) that waived the need for
consent; the data were analyzed anonymously and conducted
in accordance with the Declaration of Helsinki.
2.3. ELISA. Concentrations of IL-17A, IFN-𝛾, IL-10, IL-6, and
TIMP-1 were measured in culture supernatants by ELISA
according to the instructions of the manufacturers (R&D
System, Minneapolis, MN, USA; eBioscience San Diego, CA,
USA and BioLegend, San Diego, CA, USA). Absorbance was
detected with a microplate reader (Bio-Rad, Hercules, CA,
USA), and the I-smart program was used to calculate the
standard curve.
2.4. Intracellular Staining. CD4+ T cells (1 × 105) were
cultured for 5 days in round-bottomed 96-well plates in the
presence of anti-CD3 (1𝜇g/mL) plus anti-CD28 (1 𝜇g/mL)
mAb and in the presence of recombinant OPN-FL 1 𝜇g/mL,
OPN-N, or OPN-C 0.5 𝜇g/mL. After 5 days of culture,
the cells were restimulated with phorbol 12-myristate 13-
acetate (PMA, 50 ng/mL; Sigma-Aldrich) plus ionomycin
(500 ng/mL; Sigma-Aldrich) for 5 hours in the presence of
BFA (10 𝜇g/mL; Sigma-Aldrich). Then, cells were permeabi-
lized, stained with a PE-conjugated anti-IL-10 mAb (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany) and APC-
conjugated anti-IL-17A mAb (eBioscience, San Diego, CA,
USA), and analyzed by flow cytometry.
2.5. Cell Death Assay. Activation induced cell death (AICD)
was evaluated on T cell lines obtained by activating PBMC
with phytohemagglutinin (PHA, Sigma-Aldrich; 1𝜇g/mL)
and cultured in RPMI 1640 medium + 10% FBS + IL-2
(2U/mL; Sigma-Aldrich) for 6 days. In the AICD assay, cells
(5 × 104/well) were cultured in wells coated with anti-CD3
mAb (OKT3, 1 𝜇g/mL) with RPMI + 5% FBS + 1U/mL IL-
2 in the presence or absence of OPN-FL (1 𝜇g/mL), OPN-
N, or OPN-C (0.5 𝜇g/mL). Live cells were then counted in
each well using the trypan blue exclusion test. Assays were
performed in triplicate and results were expressed as relative
cell survival % calculated as follows: (total live cell count in
the assay well/total live cell count in the respective control
well) × 100.
2.6. Cell Migration Assay. In the Boyden chamber (BD
Biosciences) migration assay, resting PBL or HUVECs (5 ×
10
4 or 2 × 103, resp.) were plated onto the apical side
of 50 𝜇g/mL matrigel-coated filters (8.2mm diameter and
0.3 𝜇m or 0.5𝜇m pore size; Neuro Probe, Inc.; BIOMAP
snc, Milan, Italy) in RPMI or M200 serum-free medium,
with or without OPN-FL (10𝜇g/mL), OPN-N (5 𝜇g/mL), or
OPN-C (5 𝜇g/mL). Mediums containing 1 ng/mL RANTES
(R&D System) or 10 ng/mL vascular endothelial growth
factor (VEGF-𝛼, R&D System) were placed in the basolateral
chamber as a positive chemoattractant stimuli for PBL and
HUVECs, respectively. The chamber was incubated at 37∘C
under 5% CO
2
. After 20 h, the cells on the apical side were
wiped off with Q-tips. The cells on the bottom of the filter
were stained with crystal violet, and all were counted (four-
fold filter) with an inverted microscope (magnification 40x).
Data are shown as percentages of the treated cells migration
versus the control migration measured for untreated cells.
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Control migration is (mean ± SEM) 263 ± 45 cells for
HUVECs (𝑛 = 5) and 155 ± 25 for lymphocytes (𝑛 = 5).
2.7. Cells Adhesion Assay. HUVECs were grown to conflu-
ence in 24-well plates in completeM200medium (PromoCell
GmbH, Heidelberg, Germany) and then treated or not
with OPN-FL (10𝜇g/mL), OPN-N (5 𝜇g/mL), or OPN-C
(5 𝜇g/mL) for 30min, washed with fresh medium twice, and
incubated for 1 h with resting PBL (5 × 104 cell/well). The
1 h incubation time was chosen to allow full sedimentation
of the adhering cells, but similar results were obtained with
a shorter incubation time (30min). After incubation in the
adhesion assay, nonadherent cells were removed by washing
three times with M200. The center of each well was analyzed
by fluorescence image analysis. Adherent cells were counted
by the Image-Pro Plus Software for microimaging (Media
Cybernetics, Bethesda, MD, version 5.0). Data are shown as
percentages of the treated cells adhesion versus the control
adhesion measured for untreated cells. This control adhesion
was (mean ± SEM) 35 ± 4 cells per microscope field (𝑛 = 5).
2.8. Angiogenesis Assay. In the tube formation assay,
HUVECs were cultured in M200 serum-free medium
and seeded onto 48-well plates (2.5 × 104/well) previously
coated with 150 𝜇L of growth factor-reduced matrigel (BD
Biosciences) in the presence of OPN-FL (10𝜇g/mL), OPN-N
(5 𝜇g/mL), OPN-C (5 𝜇g/mL), or control medium with
VEGF-𝛼 (10 ng/mL, R&D System).
The morphology of the capillary-like structures formed
by the HUVECs was analyzed after 6 h of culture using
an inverted microscope (Leica Microsystem; magnification
10x) and was photographed with a digital camera (Leica
Microsystem). Tube formation was analyzed and the number
of tubes (with branching at both ends) was counted with an
imaging system (Image-Pro Plus software for microimaging,
Media Cybernetics, version 5.0, Bethesda, MD, USA). Tube
formation was evaluated by counting the total number of
tubes in three wells (𝑛 = 5) as previously described [41].
2.9. EAE Induction and OPN Treatment. Specific pathogen-
free female C57BL/6mice were purchased fromHarlan (Har-
lan Laboratories, Indianapolis, IN, USA). The experimental
protocol and animal handling were approved by CESAPO,
the ethical committee of theUniversity of PiemonteOrientale
(Permit Number: 10/2013). To induce EAE, eight-week-old
mice (𝑛 = 48) were immunizedwith 200𝜇g ofMOG35–55 pep-
tide (Espikem, Firenze, Italy) emulsified in complete Freund
adjuvant (Sigma-Aldrich) containing 4mg/mL heat-killed
mycobacterium tuberculosis (Difco laboratories, Detroit, MI,
USA). On the day of MOG35–55 immunization and 48 h later,
the mice were injected intraperitoneally (i.p.) with pertussis
toxin (Sigma-Aldrich, 500𝜇g in 0.1mL of PBS). The mice
were examined daily for clinical signs of EAE and scored
as reported [42]. Twenty days after the remission, mice
were divided into different experimental groups receiving
daily injection of 5 𝜇g of different OPN variants (OPN-
FL, OPN-N, OPN-C, or a mixture of OPN-C + OPN-N).
Moreover, since OPN-FL is cleaved by thrombin in vivo, we
also injected OPN-FLmut, lacking the thrombin cleavage site.
Animal health was evaluated daily, throughout the duration
of the experiment. Since the applied EAE protocol and the
treatments with recombinant OPNs do not cause a long and
intense suffering, we never administered an analgesic therapy.
To prevent malnutrition in palsy mice, starting from EAE
score 3.5 on, we put food and water directly into the cage,
where they could easily reach. No unexpected death was
recorded. Euthanasia was performed by cervical dislocation
after a light inhalational anesthesia with isoflurane (2-chloro-
2-(difluoromethoxy)-1,1,1-trifluoro-ethane) (ISOFLURANE
VET FL VT, Merial Italia SpA, PD, Italy) using a precision
out-of-circuit vaporizer (ISOTEC 4 series 1789, 2Biological
Instruments SNC, VA, Italy) in a rodent induction chamber
(2Biological Instruments SNC).
2.10. Data Analysis. The data are shown as the % of mean
± SEM. The statistical analyses were performed with Graph-
Pad Prism 3.0 software (San Diego, CA, USA) using the
Wilcoxon’s signed rank test. The Friedman ANOVA test for
repeated measures followed by Dunn’s multiple comparison
was used to analyze the daily clinical EAE score. 𝑝 values
<0.05 were considered significant.
3. Results
3.1. Production of Human and Murine Recombinant Proteins.
Both the human and murine leaderless OPN sequences,
lacking the signal sequence, were cloned into pUCOE vector
(OPN-FL). In order to assess the role of thrombin cleavage on
OPN activity, we also cloned the followingmouse and human
OPN variants: OPN-N including aa 17–168 (human) or 17–153
(mouse) of OPN; OPN-C including aa 169–314 (human) or
154–294 of OPN; OPN-FLmut carrying a mutated thrombin
cleavage site (from R
153
-S
154
to S
153
-F
154
) (Figure 1(a)) [23].
The cDNA coding for all these variants was cloned as fusion
proteins with the 6xHis Tag and stably transfected into CHO
cells. The presence of the recombinant proteins was verified
in the culture supernatants by coomassie staining and by
western blotting using antibodies designed against different
epitopes ofOPNor theHis Tag (Figure 1(b)). All recombinant
proteins displayed the expected sizes, that is, 60 kDa for
OPN-FL and OPN-FLmut, 35 kDa for OPN-N, and 25 kDa
forOPN-C, without presence of degradation products and/or
contamination by other proteins. As expected, OPN-FLmut
was not cleaved by thrombin (Figure 1(c)).
3.2. Effects of OPN on Human Immune Cells In Vitro. We
evaluated the effect of the human OPN-FL, OPN-N, and
OPN-C on secretion of IFN-𝛾, IL-17, and IL-10 by T cells,
sinceOPN is known to stimulate secretion of IFN-𝛾 and IL-17
and to inhibit secretion of IL-10 [43, 44]. CD4+ T cells from
healthy donors were activated by triggering CD3 and CD28
and cultured in the presence and absence of OPN-FL, OPN-
N, and OPN-C for 5 days. Then, secretion of IL-17A, IFN-𝛾,
and IL-10was evaluated by ELISA in the culture supernatants.
The results showed that all OPN preparations were similarly
active in increasing secretion of IFN-𝛾 (Figure 2(a)), whereas
secretion of IL-17A was significantly increased by OPN-FL
and OPN-N but not OPN-C (Figure 2(b)), and secretion of
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Figure 1: Recombinant OPN variants. (a) The figure depicts the recombinant OPN variants: OPN-FL (aa 17–314 human and aa 17–294
mouse), OPN-N including aa 17–168 (human) or 17–153 (mouse) of OPN; OPN-C including aa 169–314 (human) or 154–294 of OPN; mouse
OPN-FLmut carrying a mutated thrombin cleavage site (from R
153
-S
154
to S
153
-F
154
). (b) Western blotting showing the recombinant proteins
after purification probed with the anti-His-tag (left panel) or antibodies specific for the N (middle panel) or C-terminal portion (right panel).
(c) OPN-FL but not OPN-FLmut is cleaved by thrombin.
IL-10 was significantly decreased by OPN-FL and OPN-C
but not OPN-N (Figure 2(c)). IL-10 and IL-17 expression was
evaluated also by intracellular staining of cells restimulated
for 5 h with PMA and ionomycin after the 5-day cultures.
Cytofluorimetric analysis showed that the proportion of IL-
17A single positive cells was significantly increased by OPN-
FL and OPN-N but not OPN-C, whereas the proportions
of IL-10 single positive cells and IL-17A/IL-10 dual positive
cells were significantly decreased by all OPN preparations
(Figure 2(d)).
We evaluated the effect of the human OPN-FL, OPN-N,
and OPN-C on secretion of IL-6 and TIMP-1 in monocytes,
since OPN is known to stimulate secretion of both molecules
which play a key role in inflammation and several pathologi-
cal conditions [45, 46]. Monocytes from healthy donors were
cultured in the presence and absence of OPN-FL, OPN-N,
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Figure 2: Effect of OPN fragments on cytokine secretion. (a) IFN-𝛾, (b) IL-17A, and (c) IL-10 protein evaluated in the culture supernatants
from CD4+ T cells by ELISA or (d) by intracellular staining with anti-IL-17A and anti-IL-10 after 5 days of treatment with OPN variants. (e)
IL-6 and (f) TIMP-1 protein secreted by monocytes after 2 days of treatment with OPN variants. Data are expressed as the mean ± SE from
6 independent experiments (∗𝑝 < 0.05; ∗∗𝑝 ≤ 0.01 versus the control; §𝑝 < 0.05; §§𝑝 ≤ 0.01 versus OPN-FL; #𝑝 < 0.05; ##𝑝 ≤ 0.01 versus
OPN-C; Wilcoxon’s signed rank test).
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Figure 3: Effect of OPN variants on AICD of T cells. AICD
was induced in PHA-derived T cell lines from healthy controls in
the presence/absence of anti-CD3 and OPN variants. Results are
expressed as relative cell survival % and are the mean ± SEM from 6
experiments. (∗𝑝 < 0.05 versus the control; Wilcoxon’s signed rank
test).
and OPN-C for 2 days. Then, secretion of IL-6 and TIMP-
1 was evaluated by ELISA in the culture supernatants. The
results showed that secretion of IL-6 was induced mildly
by OPN-FL and strikingly by OPN-N, whereas OPN-C had
no significant effect (Figure 2(e)). By contrast, secretion of
TIMP-1 was similarly induced by OPN-FL, OPN-N, and
OPN-C (Figure 2(f)).
We evaluated the effect of the human OPN-FL, OPN-
N, and OPN-C in AICD of T cells, since OPN is known to
inhibit T cell AICD, which is a key mechanism of peripheral
tolerance [47]. PHA-activated T cells obtained from healthy
donors were treated with anti-CD3 mAb to induce AICD in
the presence and absence of OPN-FL, OPN-N, and OPN-C,
and cell survival was evaluated after 16 h. The results showed
that AICD was inhibited to the same extent by OPN-FL,
OPN-N, and OPN-C (Figure 3).
We evaluated the effect of the human OPN-FL, OPN-N,
andOPN-Con lymphocytemigration and adhesion to vascu-
lar endothelial cells, since OPN is known to induce both cell
adhesiveness and migration. In the migration experiments,
PBL were seeded in the upper side of a Boyden chamber
in serum-free medium; OPN-FL, OPN-N, and OPN-C and
RANTES, used as positive controls for chemoattraction of
lymphocytes, were loaded in the lower side of the Boyden
chamber. The results showed that migration of lymphocytes
was induced by OPN-FL and, to a greater extent, OPN-N,
but not OPN-C (Figure 4(a)). In the adhesion experiments,
HUVECs were treated with OPN-FL, OPN-N, and OPN-C
for 30min, washed, and then used in the adhesion assay with
PBL. The results showed that adhesion was induced by both
OPN-FL and, to a greater extent, OPN-C but not OPN-N
(Figure 4(b)).
We evaluated the effect of the human OPN-FL, OPN-N,
and OPN-C in angiogenesis in vitro by assessing migration
and tube formation on HUVECs, since OPN is known to
induce angiogenesis [48].Themigration assaywas performed
as with PBL using VEGF-𝛼 as a positive control. The results
overlapped those obtained with PBL, since migration was
induced by OPN-FL and, to a greater extent, OPN-N,
but not OPN-C (Figure 5(a)). In the tubulogenesis assay,
HUVECs were seeded onto growth factor-reduced matrigel
in the presence or absence of OPN-FL, OPN-N, and OPN-
C, and the morphology of capillary-like structures formed
by HUVECs was analyzed after 6 h. The results showed that
OPN-N and OPN-C induced high levels of tube formation,
whereas OPN-FL had a mild, although significant, effect
(Figure 5(b)).
3.3. Effect of OPN in Mouse EAE In Vivo. The first part of
this work has been performed on human cells which are the
therapeutic targets in human diseases. To assess whether the
OPN forms exert different effects also in vivo, we moved to
mouse EAE, a model of MS [32]. EAE is a T cell-mediated
autoimmune disease characterized by perivascular CD4+ T
cell and mononuclear cell infiltration, causing demyelination
areas in the central nervous system, leading to progressive
hind-limb paralysis.
Several works showed that, in the mouse, OPN displays
similar effects than in human cells in terms of cytokine
secretion [49], cell migration [50, 51], and angiogenesis [52].
Moreover, we performed pilot experiments using T cells
and OPN variants from mice, which confirmed the pattern
of OPN-FL, OPN-C, and OPN-N effects detected in the
human model in terms of secretion of IFN-𝛾, IL-17, and IL-
10, migration, and adhesion, which are key factors in EAE
pathogenesis (data not shown).
EAE can be induced by immunization with myelin pro-
teins, such as proteolipid protein (PLP) or myelin basic pro-
tein (MBP) or myelin oligodendrocyte glycoprotein (MOG)
in complete Freund’s adjuvant (CFA). In C57BL/6 mice, the
disease can be induced by immunization with the MOG
immunodominant epitope corresponding to amino acids
from 35 to 55 (MOG35–55). In this model, mice develop
progressive paralysis (relapse) followed by a stable remission.
However, administration of OPN in the remission phase
induces a prompt relapse [34]. Therefore, we induced EAE
in C57BL/6 mice and waited for the remission and, 20 days
later, we started daily injections with the OPN variants and
monitored relapse development. We compared the effect of
the mouse OPN-FL, OPN-N, OPN-C, or OPN-C + OPN-
N. Since OPN-FL in vivo is cleaved by thrombin, we also
injected OPN-FLmut, lacking the thrombin cleavage site. The
results showed that OPN-FL, OPN-C, and OPN-C + OPN-
N induced a similar strong relapse of the disease (𝑝 < 0.001)
(Figure 6), whereasOPN-N induced amild relapse (𝑝 < 0.05)
and OPN-FLmut had no significant effect.
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Figure 4: Effect of OPN variants on PBL migration and adhesion. (a) PBL were plated onto the apical side of matrigel-coated filters in 50 𝜇L
of medium in the presence or absence of either 10𝜇g/mL OPN-FL, 5 𝜇g/mL OPN-N, or OPN-C; RANTES (10 ng/mL) was loaded in the
basolateral chamber as a positive control for migration. The cells that migrated to the bottom of the filters were stained using crystal violet
and counted (5 fields for each triplicate filter) using an inverted microscope. (b) PBL were pretreated or not with OPN-FL, OPN-N, or OPN-
C (10 𝜇g/mL) for 30min, washed, and then incubated together for 1 h in the adhesion assay. Data are expressed as the mean ± SEM of the
percentage ofmigration or adhesion versus the control obtained fromuntreated cells set at 100% from 5 independent experiments. (∗𝑝 < 0.05;
versus the control; §𝑝 < 0.05; §§𝑝 ≤ 0.01 versus OPN-FL; #𝑝 < 0.05; ##𝑝 ≤ 0.01 versus OPN-C or OPN-N; Wilcoxon’s signed rank test).
4. Discussion
In this study, we produced recombinant proteins correspond-
ing to the human OPN-FL, OPN-N, and OPN-C. These
proteins were produced in an eukaryotic system in order to
ensure the posttranslational modifications influencing OPN
functions, and they were used to investigate their individual
activity on key players in the immune response, such as
lymphocytes, monocytes, and endothelial cells. We also used
the same approach to produce the mouse OPN-FL, OPN-
N, and OPN-C, together with a thrombin-resistant form of
OPN-FL in which the thrombin cleavage site was mutated
(OPN-FLmut) and assessed their individual effect in vivo on
mouse during EAE relapse.
In T cells, OPN cleavage seems not to influence the effect
on IFN-𝛾 secretion, which marks activation ofTh1 cells since
secretion of this cytokine is similarly costimulated by OPN-
FL, OPN-N, and OPN-C. This suggests that production of
IFN-𝛾 is similarly costimulated by the triggering of either
integrins or CD44, and no incremental effect is ascribable
to the integrin cryptic site exposed in OPN-N. A similar
reasoning may be applied to inhibition of AICD, which plays
a key role in switching off the immune response and was
similarly inhibited by OPN-FL, OPN-N, and OPN-C. This
was not surprising, since both the RGD-dependent triggering
of integrins and the triggering of CD44 v6-7 have been shown
to protect cells from apoptosis [53, 54].
By contrast, secretion of IL-17 and IL-10, respectively,
upmodulated and downmodulated by OPN-FL, differentially
involves the twoOPN fragments, since IL-17 upmodulation is
mainly ascribable toOPN-N,whereas IL-10 downmodulation
is mainly ascribable to OPN-C. These results are in line
with reports showing that the OPN effects on IL-17 and IL-
10 are selectively inhibited by anti-integrin and anti-CD44
antibodies, respectively [43].
The IL-17A secretion data were confirmed by intracy-
toplasmic expression of IL-17A. By contrast, the different
effects of the OPN preparations on IL-10 secretion were not
confirmed by intracytoplasmic staining of IL-10 since all
OPNs similarly decreased the proportion of IL-10+ cells. Since
cell staining was performed at day 5, whereas supernatant
analysis evaluated the overall secretion during the whole
culture time, it is possible that the supernatant differences
were ascribable to initial phases of the culture. Another point
is that all OPN preparations decreased the proportions of IL-
10/IL-17A double positive cells, which suggest that they can
work in pushing these cells toward a frankly proinflammatory
Th17 effector function [55, 56].
A similar coordinated effect of OPN fragments can be
envisaged on lymphocyte adhesion to endothelial cells and
migration, which are two key steps of lymphocyte extrava-
sation and homing into tissues. Our results, indeed, showed
that both adhesion and migration are supported by OPN-FL,
but adhesion is ascribable to OPN-C, whereas migration is
ascribable to OPN-N, and each fragment displays its effect at
higher levels than OPN-FL.
The experiment on HUVECs showed that also the OPN
effect on migration of endothelial cells was ascribable to
OPN-N and not to OPN-C. By contrast, both OPN-N and
OPN-C displayed a strikingly higher effect than OPN-FL
Journal of Immunology Research 9
0
50
100
150
200
250
300
350
VEGF-𝛼
H
U
V
EC
 ch
em
ot
ax
is 
(%
)
NT FL N C
∗§#
∗§
∗
§
Tube formation assay
0
5
10
15
20
25
30
35
N
(a) (b)
C
FL
NT
To
ta
l n
um
be
r o
f t
ub
es
VEGF-𝛼
VEGF-𝛼
NT FL N C
∗∗§§
∗∗§§∗∗§§
∗
Figure 5: Effect ofOPNvariants on angiogenesis. (a)HUVECswere plated onto the apical side ofmatrigel-coated filters in 50 𝜇L ofmedium in
the presence or absence of either 10𝜇g/mLOPN-FL, 5 𝜇g/mLOPN-N, or OPN-C; VEGF-𝛼 (10 ng/mL) was loaded in the basolateral chamber
as a positive control for migration. The cells that migrated to the bottom of the filters were stained using crystal violet and counted (5 fields
for each triplicate filter) using an inverted microscope. Results are expressed as in Figure 4. (b) In the tube formation assay, HUVECs were
plated in the presence and absence of OPN-FL (10 𝜇g/mL), OPN-N (5 𝜇g/mL), OPN-C (5 𝜇g/mL), or VEGF-𝛼 (10 ng/mL), as a control. The
morphology of capillary-like structures formed by HUVECs was analyzed 6 h after culturing. Results are expressed as means ± SEM from 3
experiments (∗𝑝 < 0.05; ∗∗𝑝 ≤ 0.01 versus the control; §𝑝 < 0.05; §§𝑝 ≤ 0.01 versus OPN-FL; #𝑝 < 0.05; versus OPN-C; Wilcoxon’s signed
rank test). Right panels show a representative tubulogenesis experiment.
in inducing tubulogenesis, which is an in vitro assay of
neoangiogenesis. These results are in line with the reports
from Senger and colleagues [48] showing that VEGF induces
OPN and 𝛼v𝛽
3
expression in endothelial cells and stimulates
cleavage of OPN by thrombin and that the resulting OPN
fragments are strongly chemotactic for endothelial cells and
promote angiogenesis [57]. However, these authors used a
mixture of the two OPN fragments obtained by in vitro
thrombin-mediated cleavage of OPN-FL, and they could
not distinguish the individual role of OPN-N and OPN-
C. Moreover, other studies have shown that, in vascular
endothelial cells, OPN enhances VEGF-𝛼 expression, which,
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𝑛 = 48 mice were immunized at day 0 with MOG35–55 peptide
to induce EAE. The mice were examined daily for clinical signs
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were randomized into different experimental groups and received
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in turn, mediates a positive feedback on OPN expression; the
blocking of this feedback signal by anti-VEGF-𝛼 antibodies
partially inhibits the OPN-induced HUVECsmotility, prolif-
eration, and tube formation [58].
In monocytes, the main finding was a marked putative
effect of thrombin cleavage on IL-6 secretion, which was
induced moderately by OPN-FL and strikingly by OPN-N,
whereas OPN-C displayed no effect. This differential effect
was detected on IL-6 but not on TIMP-1 whose secretion was
similarly induced by all OPN preparations, and this suggests
that OPN-N fine-tunes monocyte activation [32, 49, 59, 60].
Altogether our in vitro experiments show not only that
theOPNeffects on IL-17 and IL-6 secretion and cellmigration
are mainly ascribable to OPN-N, whereas those on IL-10
secretion and cell adhesion are mainly ascribable to OPN-C,
but also that these effects are exerted at higher levels by the
appropriate OPN fragment than by OPN-FL, which suggests
that thrombin-mediated cleavage plays a key role in OPN
activity. A striking gain of function was also detected in the
tubulogenesis assay in which both OPN-N and OPN-C were
much more active than OPN-FL. In the case of OPN-N, this
gain of function may be ascribed to exposure of the cryptic
integrin binding site that allows binding to integrins unbound
by OPN-FL. By contrast, it is difficult to explain it for OPN-
C, whose only known binding site is that for CD44, which
is present also in OPN-FL. Besides the possibility that OPN-
C exposes unknown cryptic binding site(s) for unknown
ligand(s), the gain of function of OPN-C might be ascribed
to removal of the N-terminal portion of OPN-FL, which
may exert a partial steric or functional interference on CD44
triggering.
Also the in vivo experiments showed that thrombin-
mediated cleavage of OPN plays a key role in OPN function,
since OPN-FL was much more effective in inducing EAE
relapses than OPN-FLmut, which is resistant to thrombin-
mediated cleavage. Therefore, the effect of OPN-FL must be
ascribed to the fragments produced by thrombin cleavage in
vivo. Use of the recombinant OPN-C and OPN-N showed
that the effect was ascribable to OPN-C, whereas OPN-
N was active only weakly. The critical role of OPN-C was
surprising, since the presence of the cryptic binding sites for
𝛼4𝛽1 would instead draw the attention to OPN-N because
𝛼4𝛽1 is involved in the homing of T cells into the central
nervous system, and it is the target of the anti-MS drug
natalizumab.
Substantial evidence indicates that OPN-FL plays a detri-
mental role in MS and EAE [32, 46, 61]. OPN-FL has been
found to be the most abundantly expressed cytokine in
the lesions of MS patients and EAE mice. Moreover, OPN
deficient mice and mice injected with anti-OPN antibodies
develop a mild EAE, whereas administration of OPN-FL
triggers relapses in several EAE models [34]. Recently, pro-
teomic analysis of MS lesions has unraveled a potential link
between the coagulation cascade and MS pathology, which
is supported by EAE data showing that administration of
the thrombin inhibitor hirudin decreases clinical severity,
demyelination, andTh1 andTh17 cytokines secretion [36, 38].
Intriguingly, thrombin activity is increased in the demyelinat-
ing lesions [37] where OPN is expressed at high levels. Our
data confirm that thrombin-mediated cleavage of OPN plays
a key role in MS relapse by exerting a dual effect. On the one
hand, they may play a key role in the homing of autoreactive
lymphocytes in the central nervous system lesions, since
OPN-N increases production of IL-17 involved in breaking
the blood brain barrier and stimulates lymphocytemigration,
whereas OPN-C increases lymphocyte adhesion to vascular
endothelial cells. On the other hand, they may support local
inflammation, since OPN-N induces secretion of IL-6 in
monocytes, OPN-C inhibits production of IL-10, and both
increase secretion of IFN-𝛾.
5. Conclusion
In conclusion, this study shows that the OPN fragments
generated by thrombin exert distinct effects on cells involved
in the immune and inflammatory response, and it suggests
that drugs targeting each fragment may be used to fine-tune
the wide effects of this cytokine.
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